25 results about "Activating macrophage" patented technology

This invention belongs to the field of plant extract technology, specifically relating to a plant extract composition for enhancing immunity. By weight, it is composed of the following raw materials: 3-5 parts Astragalus membranaceus extract, 2.5-4 parts Echinacea purpurea extract, and 1.5-3.5 parts Rhodiola rosea extract. This plant extract composition, through the scientific formulation of Astragalus membranaceus, Echinacea purpurea, and Rhodiola rosea, and an enzymatic extraction process, enhances the immunomodulatory effect. The combination of the three extracts increases the secretion of TNF-α and IL-6 by macrophages. Furthermore, the spleen lymphocyte stimulation index (SI) of the three extracts reaches 5.57, and the lymphocyte transformation rate increases from 191% to 457%. These results indicate that this plant extract composition effectively enhances the body's non-specific and cellular immune functions by activating macrophages and promoting T lymphocyte proliferation through multiple pathways, providing more comprehensive immune protection.

The present application relates to the technical field of microorganisms, and particularly relates to a bifidobacterium BGLP1 capable of regulating sugar digestion and high GLP-1 production and application thereof. Bifidobacterium bifidum The bifidobacterium BGLP1 (CGMCC No. 35718) has the abilities of inhibiting alpha-glucosidase and alpha-amylase, stimulating STC-1 cells to secrete GLP-1 and activating the intestinal glucose-lowering pathway, significantly inhibiting pancreatic lipase activity and effectively reducing dietary fat absorption, converting excess sucrose into extracellular polysaccharides to increase the probiotic function, promoting the conversion of white fat into brown fat, and activating macrophages and improving the immune function of the body. In addition, the bifidobacterium BGLP1 has strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can successfully reach the human intestinal tract.

The invention discloses an application of an RGS1 gene inhibitor in preparation of a medicine for treating obesity-related metabolic diseases, relates to the technical field of biological medicines, and particularly relates to an application of the RGS1 gene inhibitor in preparation of a medicine for treating obesity-related metabolic diseases. The inhibitor of the RGS1 gene is used for preparing a medicine for treating obesity-related metabolic inflammatory diseases, and the medicine is used for activating a PINK1 / Parkin mediated mitochondrial autophagy pathway in macrophages; the inhibitor of the RGS1 gene is a shRNA (short hairpin Ribonucleic Acid) lentiviral expression vector capable of realizing targeted silencing of RGS1 gene expression; the application of the RGS1 gene inhibitor in preparation of drugs for treating obesity-related metabolic diseases has significant beneficial effects; the drug can accurately activate a PINK1 / Parkin mediated mitochondrial autophagy pathway in macrophages, has high targeting property, and improves the safety and effectiveness of the drug.

The present application relates to the field of microbial technology, and particularly relates to bifidobacterium BB36 with improved antigen presentation ability and enriched calcium, iron and selenium, probiotics and application thereof. Bifidobacterium bifidum The present application provides bifidobacterium BB36 with activated macrophages, up-regulated immune factor expression level, and activated dendritic cells, enhanced antigen presentation ability in immune process, and enriched calcium, iron and selenium, and can be used as a biological carrier of mineral elements, in addition, can inhibit the growth of escherichia coli and staphylococcus aureus, and protect intestinal health of the body.

This invention relates to the field of pharmaceutical technology, specifically to the novel use of avenanthramide A in the preparation of drugs for repairing liver damage. Experiments have demonstrated that the addition of avenanthramide A to activated macrophages significantly promotes the expression of tumor necrosis factor-α (TNF-α). Furthermore, co-culturing macrophages stimulated with avenanthramide A with hepatocytes effectively promotes hepatocyte proliferation. The addition of a TNF-α neutralizing antibody reverses this proliferative effect. This experiment confirms that avenanthramide A can promote hepatocyte proliferation and liver damage repair by increasing TNF-α expression in macrophages. This invention provides a novel drug target for enhancing hepatocyte proliferation.

The invention discloses application of triptolide ketone in preparation of a medicine for treating sepsis lung injury, and belongs to the technical field of biological medicine. Aiming at the problems that traditional chemical synthetic drugs may cause a large amount of sequelae and antibiotic abuse, and triptolide may cause liver and kidney injury when treating sepsis, research finds that triptolide can be used for treating sepsis lung injury, and can be used for treating sepsis lung injury. According to the application, the protein expression level of HIF-1alpha in proinflammatory activated macrophages is lowered, so that aerobic glycolysis is inhibited, and the effect of treating sepsis lung injury is achieved. Compared with the triptolide alcohol, the triptolide ketone does not cause liver and kidney injury while playing a role in treating the sepsis lung injury, and the curative effect of the triptolide ketone is equivalent to that of the existing medicine 2ME2 for treating the sepsis lung injury, so that the triptolide ketone has important application potential clinically, and can be used for preparing medicines for treating the sepsis lung injury. And a theoretical basis is provided for clinically developing medicines for treating sepsis lung injury.

The application discloses a kind of nucleic acid nano vesicles based on sulfonium copolymerization peptide and its preparation method and application.The vesicle is formed by the electrostatic self-assembly of a kind of sulfonium copolymerization peptide and polynucleotide, and is stable nano vesicle with hollow structure.The vesicle is different from conventional solid nanoparticles, and its unique hollow structure provides space for co-loading other therapeutic agents (such as enzymes, chemotherapeutic drugs).The application also provides a preparation method of the nano vesicle, and its application as a carrier for simultaneously loading nucleic acid drugs and other active ingredients for synergistic treatment.The nano vesicle has extraordinary long-term storage stability, and can deliver siRNA and catalase to tumor sites, block CD47 "don't eat me" signal through gene silencing, and enzymatically degrade immunosuppressive factor H2O2 in tumor microenvironment, thereby remodeling tumor immune microenvironment, efficiently activating macrophages, dendritic cells and T cells, and producing strong synergistic anti-tumor immune effect.

The application belongs to the field of tea polysaccharide research, and discloses a Zijuan tea polysaccharide ZTPW with immunoregulatory activity, and a preparation method and application thereof. The ZTPW is a uniform polysaccharide obtained by hot water extraction and alcohol precipitation of Zijuan tea leaves, and separation and purification through an ion exchange column and a gel column, the main repeating unit structure of which is shown in the following, and the weight average molecular weight thereof is 7.73 kDa. Through in vitro immunoregulatory activity research, the ZTPW can be recognized by pattern recognition receptors TLR2 and TLR4 to activate macrophages, significantly enhance the activity of mouse monocyte macrophage RAW264.7 cells, and mediate the production of NO and cytokines of mouse monocyte macrophage RAW264.7 through MAPKs and NF-kappa B signal pathway, so as to play an immunoregulatory role. The polysaccharide can be used as a potential immunoregulator for the development of functional food or medicine.

The invention relates to a fusion polypeptide for diabetes wound repair and a pharmaceutical composition thereof, and discloses a sequence design and a preparation method of the fusion polypeptide FP-DW01-Chol, and a temperature-sensitive hydrogel composition containing the polypeptide and MitoQ. The fusion polypeptide contains a TREM2 agonist domain, an AGE-RAGE blocking domain, an MMP9 recognition cleavage site, an Angiopoietin-2 mimic peptide fragment and a cholesterol modification terminal, and can activate anti-inflammatory polarization of macrophages, block a chronic inflammation pathway and respond to a wound enzyme environment to release an angiogenesis promoting fragment. The pharmaceutical composition takes poloxamer 407 / 188 as a temperature-sensitive carrier, realizes cooperative delivery of polypeptide and MitoQ, and has the advantages of slow release, skin retention and stability. In-vitro and db / db mouse model experiments prove that the composition can remarkably promote high-glucose damaged cell activity recovery, inhibit inflammatory factor release, accelerate wound closure, promote angiogenesis and tissue remodeling, provides a multi-mechanism synergistic and local long-acting treatment scheme for diabetic refractory wounds, and has important clinical transformation value.

The present application relates to the technical field of biological medicine, in particular to a new application of a BTK PROTAC compound NX-5948, especially to a new application of a Bruton's tyrosine kinase protein degradation targeting chimera BTK PROTAC compound NX-5948 in a drug for treating secondary hemophagocytic syndrome (HLH). In the present application, the BTK PROTAC compound NX-5948 inhibits the activation of the macrophage BTK / NF-κB axis signaling pathway through targeting, on the one hand, reduces the number of activated macrophages by inhibiting the proliferation and survival of macrophages, on the other hand, induces the polarization of macrophages from pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages through the immunoregulatory effect on macrophages, and then inhibits the release of cytokines and the occurrence and development of HLH, so that the effect of the new application of the present application is that it can inhibit the abnormal activation of macrophages and improve the clinical symptoms or laboratory indexes existing in patients with secondary hemophagocytic syndrome.

The invention discloses sea cucumber glycoprotein MYP with immunocompetence and application of the sea cucumber glycoprotein MYP, and belongs to the technical field of marine biological activity. The immunocompetence protein MYP derived from the sea cucumber water extract is obtained, the MYP is obtained from the sea cucumber water extract through anion exchange chromatographic column purification, the immunomodulatory activity of the obtained protein is researched, and the result shows that the obtained sea cucumber glycoprotein can activate RAW264.7 macrophages to be converted from an M0 type to an M1 type, the phagocytic ability of the macrophages is improved, and the immunocompetence of the macrophages is improved. And the secretion of cell factors such as NO, ROS, IL-6, IL-1beta, TNF-alpha and the like can be effectively promoted. Meanwhile, the simulated digestion product of the MYP can also effectively promote the secretion of NO, ROS and cell factors of cells. And practical verification shows that the active protein MYP and the digestion product thereof have good immunomodulatory activity, and can provide technical basis and data support for subsequent industrial development.

This specification relates to compositions comprising novel amide compounds derived from amino acid structures such as valine, leucine, phenylalanine, proline, or pipecolic acid. [Solution] The composition can exert an immune-enhancing effect by activating the phagocytic activity of macrophages, which are important components of the human immune system and help eliminate pathogens.

The invention provides difunctional tremella polysaccharide as well as a preparation method and application thereof, the tremella polysaccharide is prepared by adopting a water extraction method, and the steps of crushing and sieving, hot water extraction, centrifugal separation, vacuum concentration, alcohol precipitation, Sevag deproteinization, dialysis, acidolysis, dialysis and freeze drying are performed. The trifluoroacetic acid degradation method has the characteristics of rapidness, high efficiency, simplicity and easiness in operation, the neutral sugar content of the prepared tremella polysaccharide is greater than or equal to 74%, the uronic acid content is greater than or equal to 21%, and the purity is greater than or equal to 96%. The difunctional tremella polysaccharide can significantly promote proliferation and secretion of nitric oxide NO of RAW264.7 macrophages, and significantly promote proliferation of bacteroides multiforme, bacteroides simplex, bacteroides ovale, bacteroides fragilis, bifidobacterium longum subsp. Longum, bifidobacterium breve, bacteroides bacteria, bifidobacterium bacteria and mixed bacteria. The compound has the advantages of being high in purity, activating macrophages and promoting probiotic proliferation, and can be applied to food and health care products.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BB36 capable of improving antigen presentation capacity and enriching calcium, iron and selenium, a metagen and application of the bifidobacterium bifidum BB36. The bifidobacterium bifidum BB36 disclosed by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on February 2, 2026, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.37593. The invention further discloses a preparation method of the bifidobacterium bifidum BB36. The bifidobacterium bifidum BB36 provided by the invention has the effects of activating macrophages, up-regulating the expression level of immune factors, directly activating dendritic cells and enhancing the antigen presentation capacity in the immune process, has the capacity of enriching calcium, iron and selenium, and can be used as a biological carrier of mineral elements; the growth of escherichia coli and staphylococcus aureus can be inhibited, and the intestinal health of a body is protected.

The invention relates to a hirsutella sinensis strain as well as a fermentation method and application thereof, and belongs to the technical field of microorganisms. The strain is separated from a natural cordyceps sinensis sample, and green, high-yield, stable and sustainable Hirsutella sinensis mycelia are obtained through a liquid fermentation process. The strain disclosed by the invention shows excellent growth and proliferation rates in fermentation culture, and the adenosine content of the strain is surprisingly high. In addition, the strain disclosed by the invention shows an excellent bidirectional immunoregulation effect, not only can effectively improve the immune function of macrophages in a resting state, but also has an inhibition effect on excessively activated macrophages.

The present disclosure belongs to the technical field of biological medicine, and particularly relates to the application of finerenone in the preparation of a drug for treating hypertensive renal injury. The present disclosure provides the application of finerenone in the preparation of a drug for preventing and / or treating hypertensive renal injury, specifically, by using a deoxycorticosterone acetate-salt-induced hypertensive mouse model and a primary mouse renal tubular epithelial cell-bone marrow-derived macrophage co-culture model, it is first revealed that aldosterone and salt corticosteroid receptor signals mediate cell-to-cell communication by promoting PANX1-dependent ATP release in renal tubular epithelial cells, and then activate macrophage P2X7, activate NLRP3-mediated macrophage pyroptosis, and aggravate the molecular mechanism of aldosterone-driven renal inflammation and fibrosis. The present disclosure also provides the application of a substance targeting a PANX1 / extracellular ATP / P2X7 signal axis in the preparation of a drug for preventing and / or treating hypertensive renal injury.

The application discloses a preparation method of lentinan extract, a product and application thereof, and discloses that the beta-glucan content of eight lentinus edodes varieties is quite different, and the beta-glucan content of the fruiting body of Hu Xiang F2 is the highest. The lentinan extract prepared by the application has the activity of repairing liver injury, and can inhibit the proliferation of tumor cells by activating macrophages and enhancing the phagocytosis of the macrophages.

The invention belongs to the technical field of microbial engineering, and discloses bifidobacterium animalis subsp. Lactis JJKK012 capable of producing exopolysaccharides and application of the bifidobacterium animalis subsp. Lactis JJKK012. The problem that the bifidobacterium animalis subsp. Lactis capable of producing exopolysaccharides at high yield and simultaneously exerting antibacterial and immunoregulation effects is lacked at present is solved. The preservation number of the animal bifidobacterium subsp. Lactis JJKK012 is CGMCC (China General Microbiological Culture Collection Center) No.35555, the viable count of the strain is greater than or equal to 1 * 10 < 11 > CFU / g, and the content of exopolysaccharides reaches 856.5 mg / L. The bifidobacterium animalis subsp. Lactis JJKK012 disclosed by the invention can be used for effectively activating RAW264.7 macrophages and exerting a function of enhancing immunity; meanwhile, the strain has good acid resistance, gastrointestinal fluid tolerance, antibacterial ability and cell adhesion ability, and has the function of regulating intestinal flora.

The invention provides an immune cell-tumor cell adapter and application thereof, and belongs to the technical field of biological medicine. The invention designs and prepares a novel immune cell-tumor cell adapter, namely a small molecule ligand-antibody coupled macrophage adapter (SLAME). The SLAME is obtained by coupling an antibody targeting immune cells and a small molecule ligand targeting tumor cells, and the small molecule ligand is coupled with an Fc fragment or an Fab fragment of the antibody. In SLAME, an Fc fragment of an antibody is "occupied" by a small molecule ligand; meanwhile, the small-molecule ligand in the SLAME can be combined with tumor cells in a targeted manner, macrophages combined with Fab fragments and tumor cells combined with small-molecule ligand terminals are pulled together, the phagocytic function of the macrophages is activated, and the excellent anti-tumor effect is achieved.

The invention discloses an asymmetric hydrogel dressing with double properties and a preparation method and application thereof, and belongs to the field of biomedical materials, the asymmetric hydrogel dressing has a double-layer asymmetric structure comprising a spear layer and a shield layer; wherein the spear layer is a low-crosslinking-density layer and encapsulates liposome of targeted macrophages, the liposome contains a dimer artesunate conjugate and phosphatidylserine, and the spear layer has tissue adhesion; the shield layer is a high-crosslinking-density layer and is used for providing mechanical support and foreign matter adhesion resistance; the hydrogel dressing can synergistically release artesunate and copper ions, and strongly activates autophagy of macrophages by synergistically acting on PI3K / AKT / mTOR and AMPK / mTOR signal pathways, so that chronic inflammation is relieved, collagen deposition is promoted, and wound healing is accelerated. The invention provides an innovative intelligent dressing for treating complicated chronic wounds such as diabetic foot ulcer.

The invention provides roe polypeptide hydrogel wound dressing, a preparation method and application, and belongs to the field of wound repair medical instruments, the dressing takes roe polypeptide with the sequence of GKPVWQDLRGFY as an active ingredient and Carbomer and sodium carboxymethyl cellulose dual-network gel as a carrier matrix, the polypeptide can activate macrophages to be polarized to M2 phenotype, and the hydrogel can activate macrophages to be polarized to M2 phenotype. Expression of anti-inflammatory factors such as IL-10 and TGF-1 is up-regulated, and corneal epithelial cell migration is promoted. Animal experiments show that the dressing can significantly promote rat corneal alkali burn healing, and the healing rate reaches 71.5% within 14 days, which is 24.6% higher than that of a control group.

The invention relates to the technical field of identification of idiopathic inflammatory myopathy, in particular to a biomarker for diagnosing idiopathic inflammatory myopathy and application thereof, and the biomarker comprises the following serum markers: cold-induced RNA binding protein, myeloid cell trigger receptor-1 and Toll-like receptor 4. In the biomarker provided by the invention, the CIRP can play a pathological regulation role through a transmembrane receptor. The TLR4 serves as an important bridge for linking innate immunity and adaptive immunity, and the inflammation driving effect of CIRP is mediated in systemic inflammation. TREM-1 is a core action target of CIRP, and tissue damage is amplified by activating inflammatory response of macrophages and neutrophils in various inflammatory diseases.

The invention provides a traditional Chinese medicine composition for inhibiting osteosarcoma progress by activating macrophages, and relates to the technical field of traditional Chinese medicine preparations and immunoregulation. The traditional Chinese medicine composition for inhibiting osteosarcoma progress by activating macrophages is prepared from the following traditional Chinese medicinal materials in parts by weight: 20 to 40 parts of radix astragali seu hedysari, 5 to 15 parts of bulbus fritillariae thunbergii, 20 to 40 parts of semen coicis, 20 to 40 parts of herba hedyotidis diffusae, 4 to 8 parts of radix platycodonis, 10 to 20 parts of herba salviae chinensis, 10 to 20 parts of radix cudramiae, 10 to 20 parts of pumice and auxiliary medicinal materials. According to the invention, macrophages are induced to be polarized to M1 type, so that the phagocytic ability and cytokine release of the macrophages are enhanced, and tumor cells are killed and inhibited. In-vitro and in-vivo experiments show that the traditional Chinese medicine composition can significantly enhance the anti-tumor activity of macrophages and inhibit proliferation, migration and metastasis of tumor cells, so that a safe and effective traditional Chinese medicine scheme is provided for tumor immunotherapy.

The invention discloses hippocampus glycoprotein with an immune regulation function as well as a preparation method and application of the hippocampus glycoprotein, and belongs to the technical field of biological medicines. The hippocampus glycoprotein is prepared through optimization of a membrane separation process, the hippocampus glycoprotein is an N-glycosylation and chondroitin sulfate co-modified composite glycoprotein, the protein totally contains 65 different types of N-carbohydrate chains, the ratio of sialylated N-carbohydrate chains exceeds 30%, and the carbohydrate chain structure types comprise H5N4S1, H5N4S2, H6N5S1, H6N5S2 and the like; meanwhile, rich glycosaminoglycans (GAGs) are combined on the hippocampus glycoprotein, chondroitin sulfate is taken as a main type, and the total sulfation degree is 0.4-0.6. The hippocampus glycoprotein can effectively activate macrophages and promote secretion of immune factors such as NO, TNF-alpha and IL-6, and has remarkable immunomodulatory activity. According to the hippocampus glycoprotein provided by the invention, the hippocampus glycoprotein co-modified by N-glycosylation and chondroitin sulfate is taken as an active ingredient, and is supplemented with an acceptable carrier to prepare a medicine or a health care product, so that a new direction is provided for later development and application of related functions for immunoregulation.

The application discloses a kind of recombinant biomimetic polypeptide nanomaterial for precision regulation and control macrophage polarization and application thereof, and relates to the field of bioengineering.The recombinant biomimetic polypeptide capable of self-assembling into nanofiber is prepared, and the recombinant biomimetic polypeptide material is self-assembled, which can specifically activate macrophages, make them polarize into M1 type, and the polarized macrophages have killing effect on tumor cells, so as to be expected to be applied to tumor immunotherapy.